Kura Oncology, Inc.’s Post

The KOMET-001 Phase 1b study has shown encouraging clinical activity of ziftomenib, a menin inhibitor, for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. Learn about KOMET-001 Phase 2, a registration-directed trial evaluating ziftomenib, at the 65th ASH Annual Meeting and Exposition (booth #2701) or https://lnkd.in/eEHcvHDp.

Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult The treatment of acute lymphoblastic leukemia (ALL) continues to evolve with the introduction of new agents to replace chemotherapy and improve outcomes. In this educational program, experts share their best practices for treating patients with ALL and then use a case-based format to review the latest data regarding management and discuss key clinical challenges. Register here: https://ow.ly/noAk50PwU2I #PER #PEROnline #PEROnlineActivities

In relapsed or refractory NPM1-mutant acute myeloid leukemia, FLT3-ITD co-mutations are common (49%), and prognosis is poor. In this population, only 14% of patients treated with a FLT3 inhibitor achieve a complete remission. KOMET-008 is a phase 1 trial that will examine ziftomenib, a menin inhibitor, in combination with the FLT3 inhibitor gilteritinib in patients with NPM1-m/FLT3 co-mutations. NPM1-m patients without a FLT3 co-mutation and KMT2A-r patients will receive ziftomenib in combination with FLAG-IDA or LDAC. OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

KOMET-007 is actively recruiting patients with newly diagnosed or relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-007 is a Phase 1 study to assess the safety, tolerability, and preliminary clinical activity of ziftomenib in combination with venetoclax+/-azacitadine, or standard induction cytarabine/daunorubicin (7+3) chemotherapy. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

The power of science

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universitätsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. 💡 Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch

Did you know that our IDHQ test can offer much quicker turnaround times, which facilitates timely therapeutic decisions for patients with acute myeloid leukemia patients? Learn more in this test-specific episode of "Answers From the Lab." https://bit.ly/3sJf4sW

Guidelines for Venetoclax dosing in AML A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients https://lnkd.in/de8ZVUmZ

Is guadecitabine an effective treatment for patients with relapsed/refractory acute myeloid leukemia? Check out our visual abstract of the phase III ASTRAL-2 trial here: https://loom.ly/VE71bVQ #leusm #AMLsm

Acute Myeloid Leukemia (#AML) is the most common acute leukemia affecting adults, and the development of targeted therapies is helping to improve treatment options for patients across molecularly defined subsets. At Servier, we're continuing to drive advancements in AML research as part of our ongoing commitment to improving the lives of patients. Learn more about AML: https://lnkd.in/eFA3_aYi